Trial Information

Summary: A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

Status: No longer recruiting

Protocol Number: ML17600

Sponsor: Hoffmann-La Roche AG

Company Division: Pharmaceutical

Official Scientific Title: An open-label pilot study evaluating the effect of a combination regimen of Herceptin, cisplatin, and gemcitabine on time to disease progression in patients with metastatic urothelial cancer

Brief Summary: This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer. The anticipated time on study treatment is until disease progression and the target sample size is <100 individuals. Target sample size is 22.

Study Phase: II

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Single Group
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Urinary Tract Cancer

Intervention Type: Drug

Intervention Name: trastuzumab[Herceptin]

Primary Outcome: 1. Time to progression.

Key Secondary Outcomes: 1. Efficacy: Clinical benefit rate: complete remission, partial remission, or stable disease; and overall survival. Safety: Toxicity profile (systemic and cardiac tolerability); and quality of life

Inclusion Criteria:

  • adult patients with >=18 years of age;
  • metastatic urothelial carcinoma;
  • measurable metastases or local recurrent disease;
  • no prior chemotherapy for metastatic disease;
  • HER2 overexpression (IHC [2+] or [3+]).

Exclusion Criteria:

  • concomitant chemotherapy or immunotherapy;
  • active or uncontrolled infection;
  • solely CNS metastases;
  • clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;
  • co-existing malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ;
  • women who are pregnant or breastfeeding.

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: January, 2001

Trial Registration Date: 08/29/2005

Date Last Updated: 08/18/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Aschersleben, Germany, 06449
Telephone: 973-235-5000 or 800-526-6367

  

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 20, 2008 at 2:21:17 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA